Clinical trial · Observational
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
Real World Evidence of Brentuximab Vedotin Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant
NCT04776265CI-TRIAL-00072842unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, observational real world study with prospective follow up that will evaluate the treatment approach in patients with relapsed/refractory cHL who undergo ASCT in Argentina.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma, Adult | Adult Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Refractory Hodgkin Lymphoma | Hodgkin Lymphoma | CURATED_BROADER | 0.78 |
| Relapsed Hodgkin's Disease, Adult | Adult Hodgkin Lymphoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Evaluation of therapeutical approach after ASCT | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- RR HL Who Receive Salvage Chemotherapy and ASCT
- description
- Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant
- interventionNames
- Other: Evaluation of therapeutical approach after ASCT
Primary outcomes (2)
- measure
- Evaluate proportion of patients who received Brentuximab Vedotin and ASCT.
- timeFrame
- 24 months
- description
- Study real world evidence of the proportion and characteristics of patients with relapsed refractory cHLwho undergo ASCT, who receive consolidation with BV.
- measure
- Evaluate factors that determine BV consolidation after ASCT.
- timeFrame
- 24 months
- description
- Study the factors that determine BV consolidation after ASCT in real world setting.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years or older. * All patients with histologically confirmed cHL who are primary refractory or relapse and receive ASCT as part of their salvage therapy. * Signature of the form consent for participation in the study. Exclusion Criteria: * Patients with Relapsed/Refractory cHL not suitable for ASCT.
References
Publications (0)
Data not yet available
No reference posted for this study.